Literature DB >> 7542591

Distinct signaling properties identify functionally different CD4 epitopes.

C T Baldari1, E Milia, M M Di Somma, F Baldoni, S Valitutti, J L Telford.   

Abstract

The CD4 coreceptor interacts with non-polymorphic regions of major histocompatibility complex class II molecules on antigen-presenting cells and contributes to T cell activation. We have investigated the effect of CD4 triggering on T cell activating signals in a lymphoma model using monoclonal antibodies (mAb) which recognize different CD4 epitopes. We demonstrate that CD4 triggering delivers signals capable of activating the NF-AT transcription factor which is required for interleukin-2 gene expression. Whereas different anti-CD4 mAb or HIV-1 gp120 could all trigger activation of the protein tyrosine kinases p56lck and p59fyn and phosphorylation of the Shc adaptor protein, which mediates signals to Ras, they differed significantly in their ability to activate NF-AT. Lack of full activation of NF-AT could be correlated to a dramatically reduced capacity to induce calcium flux and could be complemented with a calcium ionophore. The results identify functionally distinct epitopes on the CD4 coreceptor involved in activation of the Ras/protein kinase C and calcium pathways.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542591     DOI: 10.1002/eji.1830250708

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD).

Authors:  T Idziorek; J Khalife; O Billaut-Mulot; E Hermann; M Aumercier; Y Mouton; A Capron; G M Bahr
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

2.  A novel function for the Tec family tyrosine kinase Itk in activation of beta 1 integrins by the T-cell receptor.

Authors:  M L Woods; W J Kivens; M A Adelsman; Y Qiu; A August; Y Shimizu
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

3.  Inhibitory effect of interleukin-16 on interleukin-2 production by CD4+ T cells.

Authors:  H Ogasawara; N Takeda-Hirokawa; I Sekigawa; H Hashimoto; Y Kaneko; S Hirose
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

Review 4.  Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.

Authors:  N Chirmule; S Pahwa
Journal:  Microbiol Rev       Date:  1996-06

5.  Engagement of the cellular receptor for glycoprotein B of human cytomegalovirus activates the interferon-responsive pathway.

Authors:  K A Boyle; R L Pietropaolo; T Compton
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

6.  Engagement of the CD4 receptor affects the redistribution of Lck to the immunological synapse in primary T cells: implications for T-cell activation during human immunodeficiency virus type 1 infection.

Authors:  Alice M Nyakeriga; Carl J Fichtenbaum; Jens Goebel; Stella A Nicolaou; Laura Conforti; Claire A Chougnet
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

7.  Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins.

Authors:  C Marie; S Roman-Roman; G Rawadi
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

8.  Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4.

Authors:  Samuele E Burastero; Barbara Frigerio; Lucia Lopalco; Francesca Sironi; Daniela Breda; Renato Longhi; Gabriella Scarlatti; Silvana Canevari; Mariangela Figini; Paolo Lusso
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

9.  Boosting regulatory T cell function by CD4 stimulation enters the clinic.

Authors:  Christian Becker; Tobias Bopp; Helmut Jonuleit
Journal:  Front Immunol       Date:  2012-06-18       Impact factor: 7.561

10.  CD4 regulates susceptibility to Fas ligand- and tumor necrosis factor-mediated apoptosis.

Authors:  A Algeciras; D H Dockrell; D H Lynch; C V Paya
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.